Nicotinamide sensitizes human breast cancer cells to the cytotoxic effects of radiation and cisplatin

Oncology Reports

Volumn 33, Issue 2, 2015, Pages 721-728

  Dominguez Gomez G ^a,b   Diaz Chavez J ^b   Chavez Blanco A ^b   Gonzalez Fiero, A ^b   Jimenez Salazar J E ^a   Damian Matsumura P ^a   Gomez Quiroz L E ^a   Duenas Gonzalez A ^b,c  

^a DEPARTAMENTO DE QUÍMICA   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c Tumor Study Group AC Mexico   (Mexico)

Author keywords

BRCA1; Breast cancer; Cisplatin; Niconamide; Poly(ADP ribose) polymerase

Indexed keywords

BRCA1 PROTEIN; CISPLATIN; NICOTINAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; SMALL INTERFERING RNA; BRCA1 PROTEIN, HUMAN;

ADENOSINE DIPHOSPHATE RIBOSYLATION; ARTICLE; BREAST CANCER CELL LINE; CANCER INHIBITION; CELL VIABILITY; CONTROLLED STUDY; DNA DAMAGE; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG POTENTIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; RADIOSENSITIZATION; APOPTOSIS; BREAST TUMOR; CELL PROLIFERATION; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; IONIZING RADIATION; MCF 7 CELL LINE; METABOLISM; RADIATION RESPONSE; TUMOR CELL LINE;

APOPTOSIS; BRCA1 PROTEIN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DNA DAMAGE; DRUG SYNERGISM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MCF-7 CELLS; NIACINAMIDE; POLY(ADP-RIBOSE) POLYMERASES; RADIATION, IONIZING;

EID: 84919444238     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3661     Document Type: Article

References (31)

1. Davar D, Beumer JH, Hamieh L and Tawbi H: Role of PARP inhibitors in cancer biology and therapy. Curr Med Chem 19: 3907-3921, 2012.
2. Hirai T, Shirai H, Fujimori H, Okayasu R, Sasai K and Masutani M: Radiosensitization effect of poly(ADP-ribose) poly-merase inhibition in cells exposed to low and high liner energy transfer radiation. Cancer Sci 103: 1045-1050, 2012.
3. Michels J, Vitale I, Senovilla L, et al: Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer. Cell Cycle 12: 877-883, 2013.
4. De Soto JA, Wang X, Tominaga Y, et al: The inhibition and treatment of breast cancer with poly (ADP-ribose) polymerase (PARP-1) inhibitors. Int J Biol Sci 2: 179-185, 2006.
5. Bryant HE, Schultz N, Thomas HD, et al: Specifc killing of BRCA2-defcient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434: 913-917, 2005.
6. Farmer H, McCabe N, Lord CJ, et al: Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434: 917-921, 2005.
7. Murphy CG and Moynahan ME: BRCA gene structure and function in tumor suppression: a repair-centric perspective. Cancer J 16: 39-47, 2010.
8. Hilton JF, Hadfeld MJ, Tran MT and Shapiro GI: Poly(ADP-ribose) polymerase inhibitors as cancer therapy. Front Biosci 1: 1392-1406, 2013.
9. Gupta SC, Sung B, Prasad S, Webb LJ and Aggarwal BB: Cancer drug discovery by repurposing: teaching new tricks to old dogs. Trends Pharmacol Sci 34: 508-157, 2013.
10. Dueñas-González A, García-lópez P, Herrera LA, Medina-Franco JL, González-Fierro A and Candelaria M: The prince and the pauper. A tale of anticancer targeted agents. Mol Cancer 7: 82, 2008.
11. Surjana D, Halliday GM and Damian DL: Role of nicotinamide in DNA damage, mutaGenesis, and DNA repair. J Nucleic Acids 2010 pii:157591, 2010.
12. Knip M, Douek IF, Moore WP, et al: European Nicotinamide Diabetes Intervention Trial Group Safety of high-dose nico-tinamide: a review. Diabetologia 43: 1337-1345, 2000.
13. Virag L and Szabo C: The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev 54: 375-342, 2002.
14. Chen G and Zeller WJ: Reversal of acquired cisplatin resistance by nicotinamide in vitro and in vivo. Cancer Chemother Pharmacol 3: 157-162, 1993.
15. Kaanders JH, Bussink J and Van der Kogel AJ: ARCON: a novel biology-based approach in radiotherapy. lancet Oncol 3: 728-737, 2002.
16. Janssens GO, Rademakers SE, Terhaard CH, et al: Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: results of a phase III randomized trial. J Clin Oncol 30: 1777-1783, 2012.
17. Bernier J, Denekamp J, Rojas A, et al: ARCON: accelerated radiotherapy with carbogen and nicotinamide in head and neck squamous cell carcinomas. The experience of the Co-operative group of radiotherapy of the european organization for reseArch and treatment of cancer (EORTC). Radiother Oncol 55: 111-119, 2000.
18. Bernier J, Denekamp J, Rojas A, et al: ARCON: accelerated radiotherapy with carbogen and nicotinamide in non-small cell lung cancer: a phase I/II study by the EORTC. Radiother Oncol 52: 149-56, 1999.
19. Handfeld-Jones S, Jones SK and Peachey RD: Nicotinamide treatment in diabetes. Br J Dermatol 116: 277, 1987.
20. Niren NM: Pharmacologic doses of nicotinamide in the treatment of infammatory skin conditions: a review. Cutis 77 (1 Suppl): 11-16, 2006.
21. Kolb H and Burkart V: Nicotinamide in type 1 diabetes. Mechanism of action revisited. Diabetes Care 22 (Suppl 2): B16-B20, 1999.
22. Vallely JF, Lovegrove TD and Hobbs GE: Nicotinic acid and nicotinamide in the treatment of chronic schizophrenia. Can Psychiatr Assoc J 16: 433-435, 1971.
23. Jung-Hynes B, Nihal, M, Zhong W and Ahmad N: Role of sirtuin histone deacetylase SIRT1 in prostate cancer. A target for prostate cancer management via its inhibition? J Biol Chem 284: 3823-3832, 2009.
24. Audrito V, Vaisitti T, Rossi D, et al: Nicotinamide blocks proliferation and induces Apoptosis of chronic lymphocytic leukemia cells through activation of the p53/miR-34a/SIRT1 tumor suppressor network. Cancer Res 71: 4473-4483, 2011.
25. Evers B, Drost R, Schut E, et al: Selective inhibition of BRCA2-defcient mammary tumor cell growth by AzD2281 and cisplatin. Clin Cancer Res 14: 3916-3925, 2008.
26. Löser DA, Shibata A, Shibata AK, Woodbine LJ, Jeggo PA and Chalmers AJ: Sensitization to radiation and alkylating agents by inhibitors of poly(ADP-ribose) polymerase is enhanced in cells defcient in DNA double-strand break repair. Mol Cancer Ther 9: 1775-1787, 2010.
27. Wang T, Cui H, Ma N and Jiang Y: Nicotinamide-mediated inhibition of SIRT1 deacetylase is associated with the viability of cancer cells exposed to antitumor agents and Apoptosis. Oncol lett 6: 600-604, 2013.
28. Gong DJ, Zhang JM, Yu M, Zhuang B and Guo QQ: Inhibition of SIRT1 combined with gemcitabine therapy for pancreatic carcinoma. Clin Interv Aging 8: 889-897, 2013.
29. Dragovic J, Kim SH, Brown SL and Kim JH: Nicotinamide phar-macokinetics in patients. Radiother Oncol 36: 225-228, 1995.
30. Bernier J, Stratford MR, Denekamp J, et al: Pharmacokinetics of nicotinamide in cancer patients treated with accelerated radiotherapy: the experience of the Co-operative Group of Radiotherapy of the European Organization for ReseArch and Treatment of Cancer. Radiother Oncol 48, 123-133, 1998.
31. Horsman MR, Hoyer M, Honess DJ, Dennis IF and Overgaard J: Nicotinamide pharmacokinetics in humans and mice: a comparative assessment and the implications for radiotherapy. Radiother Oncol 27: 131-139, 1993.